Page 248 - Drug Class Review
P. 248
To compare the tolerability and cognitive effects of DON vs. RIV in patients with mild to moderate AD
Page 154 of 205
Drug Effectiveness Review Project
rivastigmine 6-12 mg/d (flexible) 12 weeks 55 Patients > 50 yrs; probable or possible AD according to DSM-IV and NINCDS; MMSE score of 10-26; CT or MRI scan within past 12 months consistent with diagnosis of AD; available caregiver SSRIs; small daily doses of neuroleptics and short-acting benzodiazepines provided they were given in
Drugs Authors: Wilkinson et al. 29 Country: Multinational (UK, South Africa, Switzerland) Eisai, Inc. and Pfizer, Inc. Study design: RCT (open label) Setting: Multi-center (19) donepezil 5-10 mg/d (flexible) 12 weeks 56 History of DON or RIV use; concomitant use of anticholinergics stable doses for at least one month prior to study entry
Alzheimer Year: 2002 Sample size: 111
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
